Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;4(3):e154-e155.
doi: 10.1016/S2665-9913(21)00418-5. Epub 2021 Dec 23.

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

L Boekel  1 , G J Wolbink  1   2   3
Affiliations

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients

L Boekel et al. Lancet Rheumatol. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

GJW received funding from ZonMw for COVID-19 research (project number 10430022010020) outside the committed work. LB declares no competing interests.

References

    1. Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2021 doi: 10.1016/S2665-9913(21)00325-8. published online Nov 15. - DOI - PMC - PubMed
    1. Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:e1870–e1885. - PMC - PubMed
    1. Boekel L, Steenhuis M, Hooijberg F, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3:e778–e788. - PMC - PubMed
    1. van Kempen ZLE, Wieske L, Stalman EW, et al. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: to wait and repopulate? Mult Scler Relat Disord. 2021;57 - PMC - PubMed
    1. Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3:e789–e797. - PMC - PubMed

LinkOut - more resources